Table 2.
A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate
| Trastuzumab (15 µg/ml) | ||||
|---|---|---|---|---|
|
|
||||
| Cell line | Cell viability | SD | Growth rate (fold change) (ΔGR) | Response |
| HCC1419 | 83.97% | 0.08 | 1.15 | R |
| HCC1596 | 117.52% | 0.09 | 0.82 | R |
| HCC1954 | 101.14% | 0.02 | 0.94 | R |
| JIMT-1 | 82.60% | 0.08 | 1.11 | R |
| BT-474 | 38.70% | 0.07 | 3.52 | S |
| BT-474.R | 85.31% | 0.11 | 1.14 | R |
| SK-BR-3 | 50.67% | 0.05 | 2.13 | S |
| SK-BR-3.R | 86.25% | 0.02 | 1.11 | R |
| AU-565 | 72.15% | 0.04 | 1.26 | S |
| AU-565.R | 93.96% | 0.06 | 0.91 | R |
| EFM-192A | 60.00% | 0.17 | 1.73 | S |
| EFM-192A.R | 98.00% | 0.10 | 0.85 | R |